Active, not recruitingPhase 3NCT05317416
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Studying Multiple myeloma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- Elranatamab(drug)
- Enrollment
- 811 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (30)
- Banner Gateway Medical Center, Gilbert, Arizona, United States
- Banner Gateway Medical Pavilion, Gilbert, Arizona, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States
- UCLA Hematology/Oncology, Los Angeles, California, United States
- UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
- Santa Monica UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
- Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- Loyola University Chicago, Maywood, Illinois, United States
- Ascentist Doctor Hospital, Leawood, Kansas, United States
- University of Michigan, Ann Arbor, Michigan, United States
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Kansas City, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05317416 on ClinicalTrials.govOther trials for Multiple myeloma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07225738A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsCity of Hope Medical Center
- RECRUITINGPHASE3NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaTakeda
- RECRUITINGPHASE4NCT07094048Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerCHU de Quebec-Universite Laval
- RECRUITINGNANCT07226934An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersWashington University School of Medicine
- RECRUITINGEARLY PHASE1NCT07294625A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1NCT07179679A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsGuangzhou Gloria Biosciences Co., Ltd.
- RECRUITINGNANCT07359014Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple MyelomaSecond Affiliated Hospital, School of Medicine, Zhejiang University